There is no evidence that antiplateletagents reduce atherosclerotic risk in patients with HF.
没有任何证据表明，抗血小板制剂降低心衰患者动脉粥样硬化的危险。
2
The PLA formation is affected variously by various antiplateletagents. Monitoring of PLA formation is helpful in guiding the clinical use and selection of antiplateletagents.
不同的抗血小板药物对PLA形成的影响有所差异，监测pla有助于指导抗血小板药的临床应用和筛选。
3
But recent reports had suggested that there might be a potentially dangerous interaction between the two drug classes whereby PPIs reduce the actual effectiveness of antiplateletagents.